Shire PLC (LON:SHP) had its price target decreased by stock analysts at Liberum Capital from GBX 4,900 ($63.81) to GBX 4,400 ($57.30) in a research report issued to clients and investors on Friday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Liberum Capital’s price objective would indicate a potential upside of 13.50% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Jefferies Group LLC reissued a “buy” rating and issued a GBX 6,400 ($83.34) target price on shares of Shire PLC in a report on Wednesday, May 3rd. Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Wednesday, June 21st. HSBC Holdings plc raised shares of Shire PLC to a “hold” rating and set a GBX 4,450 ($57.95) target price on the stock in a report on Thursday, July 6th. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a report on Friday, July 7th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a GBX 6,000 ($78.14) target price on shares of Shire PLC in a report on Tuesday, July 11th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of GBX 5,907.88 ($76.94).

Shire PLC (SHP) opened at 3835.00 on Friday. Shire PLC has a 12 month low of GBX 3,817.00 and a 12 month high of GBX 5,377.00. The firm’s market cap is GBX 34.76 billion. The company has a 50-day moving average price of GBX 4,234.98 and a 200 day moving average price of GBX 4,527.34.

TRADEMARK VIOLATION WARNING: “Shire PLC (SHP) Price Target Cut to GBX 4,400 by Analysts at Liberum Capital” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at

In related news, insider Dominic Blakemore acquired 152 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were acquired at an average price of GBX 4,255 ($55.41) per share, for a total transaction of £6,467.60 ($8,422.45).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.